Business
Biomerica Announces Positive Topline Results from the Endpoint Clinical Trial of its InFoods® IBS Treatment for Patients with Irritable Bowel Syndrome
InFoods® IBS Diagnostic-Guided Therapy is the first therapy of its kind using science, diet and technology to identify patient specific foods, which when
About this update from Biomerica, Inc.
[{"type":"text","content":"InFoods® IBS Diagnostic-Guided Therapy is the first therapy of its kind using science, diet and technology to identify patient specific foods, which when eliminated, help reduce the symptoms of IBS without the use of drugsMultiple endpoints demonstrated statistically significant improvements, indicating that the elimination of specific foods may meaningfully reduce the symptoms of IBS in all subtypes (clinical study included patients with IBS-Constipation, IBS-Diarrhea & IBS-Mixed) Greatest clinical improvements, including but not limited to pain and bloating, were seen in patients diagnosed with IBS-Mixed and IBS-ConstipationThe InFoods® IBS trial was run at leading medical institutions including Mayo Clinic, Beth Israel Deaconess Medical Center Inc., a Harvard Medical School Teaching Hospital, Houston Methodist Hospital and the University of Michigan InFoods® IBS is expected to address all IBS types that make up an approximate $30 billion market; up to 40 million Americans suffer from IBS Biomerica plans to meet with the FDA to review these results and finalize a pivotal trial for FDA clearance IRVINE, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) today announced positive topline results from the endpoint clinical trial of its InFoods® IBS diagnostic-guided therapy (DGT), with the trial showing statistically significant improvements in multiple endpoints in the Intent-to-Treat population. The InFoods® DGT is the first of its kind therapy for Irritable Bowel Syndrome (IBS) that uses a simple blood test designed to identify patient-specific foods that when removed from the diet may alleviate IBS symptoms such as pain, bloating, diarrhea and constipation. The InFoods® IBS DGT works by identifying above normal immunoreactivity to specific foods in patients. A food identified as positive is simply removed from the diet for the patient to feel better. The clinical trial was conducted by Mayo Clinic, Beth Israel Deaconess Medical Center Inc., a Harvard Medical School Teaching Hospital, Houston Methodist Hospital and the University of Michigan among others. It was a double-blinded, randomized, placebo controlled clinical trial using the InFoods® IBS therapy and was designed to select the optimal primary endpoint to be used in a pivotal trial to obtain FDA clearance. Based on this data showing...